glp-1 drugs eli lilly Lilly's New $299 Month-Long GLP‑1 Injector Shows Why It's Winning the Weight‑Loss Race StockWatch: Investors Hammer Lilly as
Description
Key findings: Prescribing trends Using a subset of Truveta Data, Truveta Research identified people who were prescribed a GLP-1 RA between January 01, 2019 and December 31, 2025
however, trials are investigating the agent in type 2 diabetes and obesity
37 Blood levels of DPP4 were lower in RA patients compared to osteoarthritis patients and showed an inverse correlation with the inflammatory marker C-reactive protein
This suggests that while GLP-1RAs may not outperform metformin in managing hormone levels, they are still beneficial in populations not already treated with metformin 23,24,25,26
